Ramelteon, marketed as Rozerem by Takeda Pharmaceuticals North America, is the first in a new class of insomnia agents selectively binds to the melatonin receptors in the suprachiasmatic nucleus (SCN), versus binding to GABA-A receptors. |
View the Top Clips from September 23, 2007
Embed This Clip In Your Site...
|
||
|
|
|||